Clinical Trial

Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)

Study acronym: COHORTE-IM
Recruiting
View on ClinicalTrials.gov →
Summary
Degenerative mitral insufficiency secondary to valve prolapse is the most common valve disease in Western countries. In the absence of specific treatment, it spontaneously progresses to heart failure and death when it is severe. Surgical mitral valve repair (or mitral plastic surgery) is the preferred treatment for primary mitral insufficiency by prolapse in case of severe leakage if associated with clinical and/or echocardiographic markers of poor prognosis (i.e., with high risk of morbi-mortality during their follow-up). It is therefore essential to refine the risk stratification of these patients in order to identify at-risk patients who should potentially benefit earlier from invasive care (cardiac surgery), or conversely, close monitoring. A number of echocardiographic and MRI parameters may have been associated with a poorer prognosis. A cohort of patients with primary mitral insufficiency (MI) will be followed to study the relationships of a set of factors to patient prognosis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-05-22; most recent amendment 2024-03-25.
Status change: Not Yet Recruiting → Recruiting 2019-10-23
Trial Details
NCT Number NCT03962023
Lead Sponsor Lille Catholic University
Collaborators: University Hospital, Lille
Conditions Mitral Valve Insufficiency
Enrollment 400 participants
Start Date 2019-09-04
Primary Completion 2034-09 (estimated)
Study Completion 2034-09 (estimated)
Updated on ClinicalTrials.gov 2024-03-26